Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer

Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer

Shots:

  • Bayer, BMS and Ono collaborate to evaluate the combination of Bayer’s Stivarga (regorafenib) with BMS & Ono’s Opdivo (nivolumab) vs regorafenib in patients with micro-satellite stable mCRC
  • The collaboration follows safety data of regorafenib as 3L monothx. in P-III CORRECT study and the efficacy data of P-I REGONIVO study evaluating the combination of regorafenib and nivolumab in Japan
  • Stivarga is an oral multi-kinase inhibitor targeting angiogenic, stromal and oncogenic receptor tyrosine kinase and is an approved therapy for patients with hepatocellular carcinoma prior treated with Nexavar. Opdivo is a PD-1 immune checkpoint inhibitor harnessing the body’s own immune system against cancer

Click here to read full press release/ article | Ref: BMS | Image: KOAM